Search This Blog

Monday, September 18, 2023

Novartis: Sandoz positive CHMP opinion for breast and gastric cancer biosimilar

 

  • Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data

  • Breast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2

  • Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolio

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.